Author:
Ali Khaled,Soond Dalya R.,Piñeiro Roberto,Hagemann Thorsten,Pearce Wayne,Lim Ee Lyn,Bouabe Hicham,Scudamore Cheryl L.,Hancox Timothy,Maecker Heather,Friedman Lori,Turner Martin,Okkenhaug Klaus,Vanhaesebroeck Bart
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014)
2. Gopal, A. K. et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008–1018 (2014)
3. Vanhaesebroeck, B. et al. P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl Acad. Sci. USA 94, 4330–4335 (1997)
4. Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nature Rev. Drug Discov. 13, 140–156 (2014)
5. Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110Δ PI 3-kinase mutant mice. Science 297, 1031–1034 (2002)
Cited by
439 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献